Skip to navigation Skip to content

Clinical Trial: Plant-Derived Oral Cannabinoid Spray to Treat Muscle Spasticity

Share

Details
Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: To improve spasticity
Number of Subjects: 446
Medication: nabiximols (an oral spray)
Location: Alabama|California|Florida|Georgia|Illinois|Indiana|Louisiana|Missouri|North Carolina|Ohio|Pennsylvania|Tennessee|Texas
Institutions: Multicenter, nationwide Contact Information
Please see link below for contact information

Funding:

Jazz Pharmaceuticals

Description

SUMMARY: Investigators are recruiting 446 people with MS worldwide who are being treated for spasticity for a study testing whether adding nabiximols (an oral spray), to ongoing antispasticity therapy can reduce MS-related muscle spasms. The study is sponsored by Jazz Pharmaceuticals.

Click here for details and contact information

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.